Article Information
History
- November 1, 2020.
Article Versions
- Version 1 (May 22, 2020 - 10:48).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Laurent Chouchana, PharmD PhDa,□,*,
- Sana Boujaafar, PharmDb,□,
- Ines Gana, PharmD PhDb,
- Laure-Hélène, Preta PharmDa,
- Lucile Regard, MD PhDc,
- Paul Legendre, MD PhDd,
- Celia Azoulay, MDd,
- Etienne Canouï, MDe,
- Jeremie Zerbit, PharmDf,
- Nicolas Carlier, MDc,
- Benjamin Terrier, MD PhDd,
- Solen Kernéis, MD PhDe,
- Rui Batista, PharmDf,
- Jean-Marc Treluyer, MD PhDa,b,
- Yi Zheng, PhDb and
- Sihem Benaboud, PharmD PhDb
- aRegional Pharmacovigilance Center, Pharmacology Department, Cochin Hospital, AP- HP.Centre – Université de Paris. Paris, France
- bPharmacology Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris, France
- cPneumology Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris, France
- dInternal Medicine Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris, France
- eAntimicrobial Stewardship, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris, France
- fPharmacy Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris, France
- ↵*Corresponding author:
Dr Laurent Chouchana. Regional Pharmacovigilance Center, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75014 Paris. Tel +33158414210; Mail laurent.chouchana{at}aphp.fr
↵□ These authors equally contribute to this work; order is based on internal agreement.
Posted November 01, 2020.
Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a short communication
